Recent breakthroughs in metastatic uveal melanoma: a cause for optimism?

Future Oncol. 2018 Jun;14(14):1335-1338. doi: 10.2217/fon-2018-0116. Epub 2018 May 9.
No abstract available

Keywords: IMCgp100; MEK inhibitors selumetinib; checkpoint inhibitors; immunotherapy; tumor infiltrating lymphocytes; uveal melanoma.

Publication types

  • Editorial

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Clinical Trials, Phase III as Topic
  • Costimulatory and Inhibitory T-Cell Receptors / antagonists & inhibitors
  • Humans
  • Immunotherapy / methods*
  • Immunotherapy / trends
  • Liver Neoplasms / mortality
  • Liver Neoplasms / secondary
  • Liver Neoplasms / therapy*
  • MAP Kinase Signaling System / drug effects
  • Melanoma / mortality
  • Melanoma / pathology
  • Melanoma / secondary
  • Melanoma / therapy*
  • Skin Neoplasms / mortality
  • Skin Neoplasms / pathology*
  • Treatment Outcome
  • Uveal Neoplasms / mortality
  • Uveal Neoplasms / pathology
  • Uveal Neoplasms / secondary
  • Uveal Neoplasms / therapy*

Substances

  • Costimulatory and Inhibitory T-Cell Receptors

Supplementary concepts

  • Uveal melanoma